Zacks' 7 Best Stocks for June, 2013
FREE Report for Zacks.com
Visitors Only

They're hand-picked from the list of Zacks Rank #1 Strong Buys. Our experts predict that their prices will jump the soonest.

Today, you can see them free.

Close This Panel X

Are you a new Zacks Member or a visitor to Zacks.com?

Recent Quotes

No Recent Quote currently available

My Portfolio

My Portfolio Tracker

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Stocks on the Move 06/17/2013

Company Name Symbol %Change
GLOBAL GEOPH GGS
7.79%
STAAR SURGIC STAA
6.23%
KAPSTONE PAP KS
6.14%
HORNBECK OFF HOS
5.99%
ANIKA THERAP ANIK
5.55%

CSC-NHS Tussle Ends, Deal Renewed

by Zacks Equity Research

September 05, 2012 | Comments : 0 Recommended this article: (0)

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Virginia-based tech giant Computer Sciences Corporation (CSC - Analyst Report) finally saw the end to its long-drawn dispute with the U.K. government’s National Health Service (NHS), which agreed to renew the existing contract for a period of four years. Computer Sciences will therefore continue to provide technological support to healthcare organizations under the NHS trust.

The NHS is a government-funded healthcare system to serve citizens of England and other parts of the U.K. Contracts to support the NHS with technological products and solutions are delegated by the U.K. Department of Health (DoH). In 2002, the DoH initiated a program (NHS National Programme for IT) to enhance the scope of NHS. Computer Sciences was selected as one of the prime contractors to support the program.

But in September last year the government decided to scrap the whole program as the contractors were found incapable of delivering the necessary IT services required for the NHS program. Computer Sciences was also held responsible due to its inability to meet the project deadline.

Though the contract was not terminated at the time, the U.K. DoH reduced the scope and value of the contract for Computer Sciences. The revised terms required CSC to install IT systems in the Midlands, North and East of England.

The issue has been under consideration for the past few months. Now, after securing approval from related government officials, it has been finalized that Computer Sciences will deploy and implement an electronic patient record system within the NHS, through its Lorenzo Regional Care software products. Computer Sciences will also be allowed to serve the NHS across England, instead of the previously determined areas of the Midlands, North and East of England.

The uncertainty regarding the NHS issue was actually weighing on Computer Sciences’ shares, which have been on a decline over the past few months. But now we believe that the contract revival will act as a catalyst, driving up share prices.

Despite strong European exposure, strained federal budgets and stiff competition from Accenture plc (ACN - Snapshot Report) and Hewlett-Packard Company (HPQ - Analyst Report), Computer Sciences retains a Zacks #2 Rank, implying a short-term Buy rating, mainly on the resolved NHS issue.

Email Print Share Rate Pos Rate Neg

Read/Post Comments (0) | Recommended this article (0)

Please login to Zacks.com or register to post a comment.

Zacks Research is Reported On:

Zacks Investment Research

is an A+ Rated BBB

Accredited Business.